Your browser doesn't support javascript.
loading
PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause.
Hou, Xiukun; Tian, Mengran; Ning, Junya; Wang, Zhongyu; Guo, Fengli; Zhang, Wei; Hu, Linfei; Wei, Songfeng; Hu, Chuanxiang; Yun, Xinwei; Zhao, Jingzhu; Dong, Qiman; Ruan, Xianhui; Li, Dapeng; Gao, Ming; Zheng, Xiangqian.
Afiliação
  • Hou X; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Tian M; Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
  • Ning J; Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center, Tianjin,300121, China.
  • Wang Z; School of Medicine, Nankai University, Tianjin 300071, China.
  • Guo F; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Zhang W; Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
  • Hu L; Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center, Tianjin,300121, China.
  • Wei S; School of Medicine, Nankai University, Tianjin 300071, China.
  • Hu C; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Yun X; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Zhao J; Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
  • Dong Q; Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center, Tianjin,300121, China.
  • Ruan X; School of Medicine, Nankai University, Tianjin 300071, China.
  • Li D; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Gao M; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
  • Zheng X; Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300040, China.
Int J Biol Sci ; 19(12): 3970-3986, 2023.
Article em En | MEDLINE | ID: mdl-37564214
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article